Company intelligence / Profile preview

Pattern Computer

Friday Harbor, Washington, United States

Ownership: Private
Employees: ~26
Development stage: Other

Overview

Pattern Computer has identified promising gene-expression patterns and developed drug combinations for TNBC and ovarian cancer currently in vitro and early testing; the ProSpectral™ device is in late-stage development for rapid, highly accurate disease detection including Covid-19, with expected FDA-compliant differentiation between major respiratory infections[1][6].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeDeviceDrug combinations (repurposed/FDA-approved drugs)
Industry: Biotech

Drug pipeline

1 asset

PCI020302

Preclinical

Partnerships

Fred Hutch Cancer Center (colorectal cancer research)[1]Undisclosed Wall Street firms (for financial RC/XAI application)[5]

Beyond the preview

Go deeper on Pattern Computer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pattern Computer.

Explore the full profile